Nichole Tucker is a Senior Editor for Targeted Oncology, a publication of MJH Life Sciences. With a focus on oncology, her work covers a range of topics including treatment advancements, clinical trials, and the impact of new therapies on patient outcomes. Nichole's articles have been featured in various publications including Urology Times, Cancer Network, and OncLive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Nichole Tucker focuses on healthcare and pharmaceutical topics, with a strong emphasis on citing data. She would likely be receptive to pitches that provide access to new or significant clinical trial results, FDA approvals, and advancements in cancer treatment.
Given her focus on scientific themes and citation of data, she may also welcome pitches from experts who can offer analysis or commentary based on the latest research findings within the fields of cancer treatment, clinical trials, biomarkers, and advanced cancers.
As Nichole's geographic focus is not specified but her coverage seems international in scope as it relates to scientific developments in healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nichole Tucker
Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.
By: Nichole Tucker
In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with patients with intrahepatic cholangiocarcinoma.
By: Nichole Tucker
Activation of the JAK/STAT pathway with ruxolitinib may be a future option for patients with newly diagnosed, high-grade glioma.
In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.
By: Nichole Tucker
In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.
By: Nichole Tucker, Sabrina Serani
In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.
MJH Life Sciences ™ - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
By: Nichole Tucker
Treatment with luspatercept led to decreases in red blood cell transfusion (RBCT) burden compared to epoetin alfa in patients with erythropoiesis-stimulating agent (ESA)-naive lower-risk myelodysplastic syndromes (LR-MDS).1
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), vibecotamab appeared well-tolerated and safe with no dose reductions required and no patients discontinuing treatment due to adverse events (AEs).
By: Nichole Tucker
The FDA has granted approval to concizumab-mtci injection (Alhemo) for the prevention or reduction in frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B with inhibitors, according to an announcement issued by Novo Nordisk.1
(833) 317-6278 
